Bactiguard Holding (BACTI-B.ST) Stock Analysis & AI Equity Report
Bactiguard Holding (BACTI-B.ST) overview
Bactiguard Holding (BACTI-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Bactiguard Holding reported revenue of SEK 244m and operating profit of SEK -28.9m; the year-end share price was N/A and market capitalisation was N/A. Bactiguard Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bactiguard Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Bactiguard Holding
Bactiguard Holding AB develops and licenses a biocompatible coating technology for medical devices that helps prevent device-related infections by reducing bacterial adhesion and biofilm formation. Through partnerships with global MedTech companies, it applies the technology to products such as catheters and other devices, and it also offers a smaller wound care portfolio.
Generate the Bactiguard Holding report
Bactiguard Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Bactiguard Holding and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.